Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 608 shares of Natera stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $120.76, for a total transaction of $73,422.08. Following the transaction, the chief financial officer now directly owns 74,014 shares in the company, valued at approximately $8,937,930.64. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Michael Burkes Brophy also recently made the following trade(s):
- On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $99.65, for a total value of $185,946.90.
- On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $102.77, for a total value of $127,229.26.
- On Thursday, July 25th, Michael Burkes Brophy sold 690 shares of Natera stock. The stock was sold at an average price of $105.29, for a total value of $72,650.10.
Natera Stock Down 0.5 %
Watch this before it gets removed
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
NTRA stock opened at $119.95 on Wednesday. The stock has a 50-day simple moving average of $123.43 and a two-hundred day simple moving average of $110.98. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $133.54. The firm has a market capitalization of $14.73 billion, a PE ratio of -38.45 and a beta of 1.53. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34.
Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same quarter in the prior year, the firm posted ($0.97) EPS. Natera's revenue was up 58.1% on a year-over-year basis. On average, equities analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.
Institutional Investors Weigh In On Natera
A number of institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC increased its stake in Natera by 1,073.1% in the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company's stock worth $7,118,000 after acquiring an additional 60,127 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Natera by 15.1% during the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company's stock worth $6,810,000 after purchasing an additional 9,781 shares in the last quarter. Natixis bought a new position in shares of Natera in the first quarter worth approximately $758,000. Allspring Global Investments Holdings LLC raised its stake in Natera by 19.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 863,406 shares of the medical research company's stock valued at $78,967,000 after purchasing an additional 143,246 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft bought a new stake in Natera during the second quarter valued at approximately $478,000. Hedge funds and other institutional investors own 99.90% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on NTRA. UBS Group decreased their price objective on shares of Natera from $160.00 to $145.00 and set a "buy" rating for the company in a report on Friday, August 9th. Stephens restated an "overweight" rating and set a $125.00 price target on shares of Natera in a research note on Friday, August 9th. Robert W. Baird lifted their price target on shares of Natera from $117.00 to $120.00 and gave the stock an "outperform" rating in a report on Friday, August 9th. StockNews.com raised Natera from a "sell" rating to a "hold" rating in a report on Thursday, October 17th. Finally, The Goldman Sachs Group raised their target price on Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, October 16th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $124.44.
Get Our Latest Stock Analysis on Natera
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
